A Phase II/III Study of High-dose Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme

  • End date
    Jan 1, 2022
  • participants needed
  • sponsor
    VU University Medical Center
Updated on 1 May 2021
platelet count
measurable disease
neutrophil count
glioblastoma multiforme
recurrent glioblastoma
stereotactic radiosurgery


In this study the investigators will evaluate the effect of high-dose, intermittent sunitinib versus treatment with lomustine in patients with recurrent glioblastoma multiforme. The investigators hypothesize that sunitinib, when given in a high-dose, intermittent schedule, will achieve adequate concentration levels in the tumor and will, besides its anti-angiogenic properties, inhibit gliomagenesis by inhibition of multiple kinases.


Study design: Multicenter, phase II/III, randomized clinical trial with high-dose sunitinib versus lomustine (CCNU) in patients with recurrent GBM.

Hypothesis: Sunitinib, when given in a high-dose, intermittent schedule, may exhibit improved efficacy in patients with recurrent GBM with an acceptable toxicity profile, compared to lomustine.

Study population: Adult patients with recurrent GBM.

Primary objective:

  • To determine the effect of high-dose sunitinib versus lomustine on six-month progression-free survival (PFS6) in patients with recurrent GBM, using the RANO criteria.

Secondary objectives:

  • To determine the effect of high-dose sunitinib on overall survival (OS 9, OS 12) in patients with recurrent GBM.
  • To assess the objective radiological response rate, using the RANO criteria.
  • To assess toxicity, using the Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0.
  • To assess patient-oriented criteria: steroid use and health-related quality of life (reported by patients and caregivers/relatives).
  • To explore the potential value of blood markers for molecular diagnostics, disease and response monitoring.
  • To explore if MGMT promoter methylation status modulates the response to sunitinib.

Treatment: After randomization, 100 patients will be divided equally over two treatment groups and will receive:

  • Group 1 (experimental arm): Sunitinib, 700 mg administered orally every 2 weeks.
  • Group 2 (control arm): Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.

Disease will be assessed by MRI according to an uniform neuro-oncology protocol every 6 weeks for the first 6 months and every 12 weeks until documented progression. Safety profile of both treatment strategies will be assessed separately for each cycle of therapy and every 12 weeks after the end of treatment if adverse effects have not resolved or are newly emerging. Furthermore, quality of life assessment takes place every 6 weeks using questionnaires.

Condition Glioblastoma Multiforme, Glomerular Basement Membrane, Malignant neoplasm of brain, Brain Tumor (Pediatric), Glioblastoma, Adult, Brain Cancer, Brain Tumor, Glioblastoma, Adult, Glioblastoma, Adult, recurrent brain tumors, glioblastoma, Glioblastoma, Adult, Glioblastoma, Adult, Glioblastoma, Adult
Treatment Sunitinib, Lomustine
Clinical Study IdentifierNCT03025893
SponsorVU University Medical Center
Last Modified on1 May 2021


Yes No Not Sure

Inclusion Criteria

Signed (by the patient or legally acceptable representative) and dated Informed Consent Form
Histologically confirmed de novo or secondary glioblastoma with unequivocal first progression, at least 3 months off radiotherapy
No more than one line of chemotherapy (concurrent and adjuvant temozolomide based chemotherapy including in combination with another investigational agent is considered one line of chemotherapy). Chemotherapy must have been completed at least 4 weeks prior to randomization
Patients may have undergone surgery for recurrence. If operated, residual and measurable disease after surgery is not required but surgery must have confirmed the recurrence
No radiotherapy, stereotactic radiosurgery or brachytherapy as treatment for recurrence
Patients must have a Karnofsky Performance Score 70%
Patients need to have adequate hematological, renal and hepatic function as assessed by the following laboratory requirements to be conducted within seven days prior to start study treatment
Hemoglobin 7.0 mmol/L
Absolute neutrophil count (ANC) 1.5 x 109/L
Platelet count 100 x 109/L
ALAT and ASAT 2.5 x ULN
Serum creatinine eGFR 50 ml/min
Albumin 25 g/L
Age 18 years

Exclusion Criteria

Evidence of a significant uncontrolled concomitant disease, such as cardiovascular disease (including stroke, New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to screening, unstable arrhythmia, clinically significant valvular heart disease and unstable angina); nervous system, pulmonary (including obstructive pulmonary disease and history of symptomatic bronchospasm), renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture
Patients with a prior (< 5 years) or concomitant second malignancy
Prior radiotherapy in the abdomen or in the lungs or in more than 3 vertebrae in the spine (Less than 3 vertebrae are considered a small radiation field and eligibility will be decided on an individual basis from the PI)
Poorly controlled hypertension despite adequate blood pressure medication. Blood pressure must be 160/95 mmHg at the time of screening on a stable antihypertensive regimen. Blood pressure must be stable on at least 2 separate measurements
Known active bacterial, viral, fungal, mycobacterial, or other infection (including HIV and atypical mycobacterial disease, but excluding fungal infection of the nail beds.)
Initial MR-scan of the brain showing intratumoral hemorrhage, except for stable post-operative grade 1 hemorrhage
Known hypersensitivity to sunitinib or to its excipients
Presence of any significant central nervous system or psychiatric disorder(s) that would interfere with the patient's compliance
Use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic (as opposed to prophylactic) purposes
Drug or alcohol abuse
Use of strong hepatic enzyme-inducing antiepileptic drugs, such as carbamazepine, phenobarbital and phenytoin. If a patient uses one or more of these specific antiepileptic drugs, they must switch to an antiepileptic drug that does not interact with cytochrome P450 (CYP450) liver enzymes, such as levetiracetam, prior to the start of study treatment
Females who are pregnant or breast-feeding
Any evidence of a disease or condition that might affect compliance with the protocol or interpretation of the study results or render the patient at high risk from treatment complications
Unwillingness or inability to comply with study and follow-up procedures
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note